We are live on
!
Find out more
DGM
Darwin Global Management Portfolio holdings
AUM
$3.77B
1-Year Est. Return
307.72%
This Fund
S&P 500
This Quarter
Est. Return
+53.03%
1 Year Est. Return
+307.72%
3 Year Est. Return
+2,873.14%
5 Year Est. Return
+48,315.58%
10 Year Est. Return
–
AUM
$751M
AUM Growth
+$242M
(+47%)
Cap. Flow
+$161M
Cap. Flow
% of AUM
21.45%
Top 10 Holdings %
Top 10 Hldgs %
97.18%
Holding
17
New
9
Increased
3
Reduced
–
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vaxcyte
PCVX
|
+$150M |
| 2 |
NUVL
Nuvalent
NUVL
|
+$110M |
| 3 |
Biohaven
BHVN
|
+$73.1M |
| 4 |
Beam Therapeutics
BEAM
|
+$66M |
| 5 |
ALPN
Alpine Immune Sciences Inc
ALPN
|
+$58.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AMAM
Ambrx Biopharma Inc
AMAM
|
+$238M |
| 2 |
TG Therapeutics
TGTX
|
+$69.1M |
| 3 |
MoonLake Immunotherapeutics
MLTX
|
+$62.8M |
| 4 |
Cytokinetics
CYTK
|
+$50.1M |
| 5 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$7.03M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Vaxcyte
PCVX
$8.12B
| $188M | 25.02% |
2,750,804
+2,170,845
| +374% | +$150M |
|
|
NUVL
2
DELISTED
Nuvalent
NUVL
| $108M | 14.36% |
1,436,964
+1,379,266
| +2,390% | +$110M |
|
3
Keros Therapeutics
KROS
$211M
| $95.1M | 12.66% |
1,435,950
+375,523
| +35% | +$22.3M |
|
|
4
Biohaven
BHVN
$2.32B
| $80.8M | 10.75% |
+1,476,974
| New | +$73.1M |
|
|
ALPN
5
DELISTED
Alpine Immune Sciences Inc
ALPN
| $78.6M | 10.46% |
+1,982,016
| New | +$58.5M |
|
|
6
Beam Therapeutics
BEAM
$2.83B
| $70M | 9.32% |
+2,119,598
| New | +$66M |
|
7
Apogee Therapeutics
APGE
$10.1B
| $55.3M | 7.36% |
+832,198
| New | +$36.3M |
|
8
Xencor
XNCR
$1.3B
| $24.6M | 3.27% |
+1,109,650
| New | +$24M |
|
9
Spyre Therapeutics
SYRE
$8.7B
| $17.9M | 2.39% |
+473,200
| New | +$13.7M |
|
|
ELEV
10
DELISTED
Elevation Oncology
ELEV
| $12M | 1.59% |
+2,332,928
| New | +$7.56M |
|
|
TRML
11
DELISTED
Tourmaline Bio
TRML
| $10.6M | 1.42% |
+465,000
| New | +$16.4M |
|
12
Merck
MRK
$315B
| $10.5M | 1.4% |
+79,600
| New | +$9.81M |
|
|
13
Cytokinetics
CYTK
$10.9B
| – | – |
-600,000
| Closed | -$50.1M |
|
|
14
MoonLake Immunotherapeutics
MLTX
$1.64B
| – | – |
-1,039,289
| Closed | -$62.8M |
|
|
SWTX
15
DELISTED
SpringWorks Therapeutics
SWTX
| – | – |
-192,734
| Closed | -$7.03M |
|
|
16
TG Therapeutics
TGTX
$8.4B
| – | – |
-4,046,598
| Closed | -$69.1M |
|
|
AMAM
17
DELISTED
Ambrx Biopharma Inc
AMAM
| – | – |
-16,688,636
| Closed | -$238M |
|
Similar funds
VVP
ABC
SCA
ACH
GL
VA
GCC
SB
Darwin Global Management's Q1 2024 Portfolio in Review
As of Q1 2024, Darwin Global Management held 17 positions worth $751M, up 47% from $509M the previous quarter. Its ten largest holdings account for 97% of the portfolio.
Darwin Global Management deployed $161M of net new capital in Q1 2024, opening 9 new positions and adding to 3 existing holdings. Its largest new stake was Biohaven: 1,476,974 shares worth $80.8M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the most notable exit was Ambrx Biopharma Inc, an estimated $238M sold.
- Darwin Global Management's largest Q1 2024 buy was Biohaven: 1,476,974 shares worth $80.8M.
- Darwin Global Management added most to Vaxcyte in Q1 2024, an estimated $150M increase.
- Darwin Global Management fully exited Ambrx Biopharma Inc in Q1 2024, selling an estimated $238M.
- Darwin Global Management's ten largest holdings make up 97% of its $751M portfolio in Q1 2024.
- Darwin Global Management opened 9 new positions and closed 5 in Q1 2024.
- Darwin Global Management's portfolio value rose 47% quarter-over-quarter to $751M.
Based on Darwin Global Management's 13F filing for Q1 2024, filed 15 May 2024.